Zimmer Biomet (ZBH) is trading lower as the market reacts to its first-quarter 2026 update and a finance-leadership transition announced on April 28, 2026. Even with a headline beat on earnings and higher adjusted EPS and free-cash-flow expectations, trading has focused on the quality of the quarter—particularly profitability/margin signals—and the added uncertainty of a CFO change during an ongoing commercial transformation.

For the quarter ended March 31, 2026, Zimmer Biomet reported net sales of $2.087 billion and adjusted diluted EPS of $2.09. Management emphasized steady end-market demand and momentum from newer products, while maintaining its full-year 2026 organic constant-currency revenue growth framework of 1% to 3%—a stance that can read as conservative after a beat and can amplify investor focus on whether margins and execution are trending cleanly enough to justify a higher multiple.

Zimmer Biomet also announced that CFO Suketu Upadhyay will depart effective April 28, 2026, and that Paul Stellato (controller and chief accounting officer) will serve as interim CFO while a permanent search is conducted. The timing—paired with earnings—can increase perceived risk for investors, especially when the company is navigating operational changes and investors are already scrutinizing margin and cost dynamics.

Key near-term catalysts include follow-through on profitability and any incremental disclosure around the pace and impact of the U.S. commercial/sales-channel transformation. Investors will also watch for clarity on the CFO succession process, continuity in capital allocation and working-capital discipline, and whether upcoming quarters show improving margins alongside sustained procedure volume demand.